BioStock: Iconovo carries out directed share issue for continued value creation
Recently, Iconovo carried out a directed share issue that strengthened the cash position by 55 MSEK, enabling continued value creation in 2023. The capital injection will be used to negotiate an agreement for the company’s most recently developed inhaler ICOpre, as well as move the ICOcap project forward and establish the subsidiary Iconovo Pharma. Iconovo also plans to leverage the opportunity within nasal inhalation after seeing positive results for ICOone Nasal in the pandemic project with the Bill & Melinda Gates Foundation.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se